COVID-END partners coordination call
Notes from 17 June 2021

1. INTRODUCTIONS
   a. Jeremy ‘re-welcomed’ Euphrasia Ebai-Atuh Ndi, a citizen partner from Cameroon
   b. He also welcomed Justine Karpusheff, a representative from NICE

2. REVIEW OF COVID-END ACTION ITEMS
   a. Jeremy pointed partners to the notes from 3 June (see attachment 2)

3. COVID-END NETWORK UPDATES
   a. Jeremy introduced potential COVID-END legacy projects and asked partners to consider the legacies they would like to leave as partners in COVID-END and as members of particular COVID-END working groups
      i. WG1 Scoping - Lancet paper authored by COVID-END partners
      ii. WG2 Prioritizing - Excel, matchmaking & paper
      iii. WG3 Accessing - inventory/database +/- transition to lessons learned for future
      iv. WG4 Engaging - GCESC exhibits via webinars and listserv
      v. WG5 Recommending - retired(?) (the legacy was resources)
      vi. WG6 Sustaining - evaluation paper(s)
      vii. WG7 Advocating - Cochrane convenes event
      viii. TG1 Equity - addition of column to inventory
      ix. TG2 Citizen partners – paper
      Kerry noted that it would be good to also produce a cross-cutting paper on the COVID-END experiment across all working groups and other activities (and Jeremy and David Gough suggested that this may be something that the Scoping working group could take up)

**ACTION:** Working-group co-chairs to consider initiating discussions about legacy projects with their respective working groups

b. John provided an update on the Global Commission on Evidence to Address Societal Challenges
   i. Eight commissioners have been confirmed and we are awaiting confirmations from additional commissioners
   ii. Some funding has been confirmed and many promising conversations with potential funders are underway
   iii. Report will comprise six chapters, be ‘exhibits’ heavy (with many infographics, etc.), include recommendations (and note where recommendations align with those from other commissions), and be published in six languages; feedback on draft exhibits will be elicited over the coming months
   iv. Timeline includes a six-month-long report-preparation process (June to November, with the report being published in December) and with 2022 being about pursuing pathways to influence
v. Pathways to influence include advisors (intermediary organizations and individuals with a deep familiarity with the four types of decision-makers, related commissions and initiatives, and funders), events (where feedback on the exhibits can be elicited and pathways to influence pursued), COVID-END partners (who we hope will provide input and promote recommendations), and electronic mechanisms (e.g., listservs, webinars, etc.)

vi. There are two current requests of COVID-END partners, which are listed below as actions

c. **ACTION:** Partners to review the draft exhibit listing key developments in the field of using evidence to address societal challenges and suggest any that are missing

d. **ACTION:** Partners to review the list of key meetings being planned over the next year and suggest any that are missing

e. Partners agreed to change the COVID-END partners meeting frequency to monthly

**ACTION:** Safa to update the calendar invitations to include only the following dates:

i. July 29

ii. September 9

iii. Early to mid October (exact date to be confirmed)

iv. November 4

v. December 2

4. NEWS AND INITIATIVES OF INTEREST TO PARTNERS


   i. Dates: 25 to 27 October 2021

   ii. Abstract submission and registration now open

   iii. For more information, link [here](#)

   b. Zac also described a cross-partner event bringing together evidence and guideline groups from Australia and New Zealand: [https://www.engagingevidence.com](https://www.engagingevidence.com) (November 2021)

5. ANY OTHER BUSINESS

   a. Jeremy suggested that we bring back to a future meeting a point raised by Maureen Dobbins in the chat box: “For consideration, not necessarily for discussion today, do you see COVID-END continuing in some way post COVID to continue: collaborating on producing high quality evidence syntheses in response to decision/policy maker needs, reduce duplication, continue to discuss and debate methods for rapid reviews and other knowledge products; and continue to evolve methods for measuring/gauging impact?

   **b. ACTION:** Safa to add this to a future agenda

   c. Kerry Albright noted that UNICEF Innocenti has “several individual evidence synthesis consultancies coming up at UNICEF-Innocenti to help produce EGM's/Rapid Evidence Assessments on Children and Adolescents and (I) mental health (ii) child labour and education and (iii) disability”

   **d. ACTION:** Kerry to share vacancy announcements via Twitter, tagging COVID-END, and partners to consider sharing among their networks